martin-metabolicreprogramming-2018.pdf (1.14 MB)
Metabolic reprogramming in type 2 diabetes and the development of breast cancer
journal contribution
posted on 2018-05-01, 00:00 authored by Sheree MartinSheree Martin, Sean McgeeSean McgeeA wealth of epidemiological data has found that patients with type 2 diabetes have a greater risk of developing breast cancer. The molecular mechanisms underpinning this relationship are yet to be elucidated; however, this review examines the available evidence suggesting that the metabolic abnormalities observed in type 2 diabetes can predispose to the development of breast cancer. Alterations in substrate availability and the hormonal milieu, particularly hyperinsulinemia, not only create a favorable metabolic environment for tumorigenesis, but also induce metabolic reprogramming events that are required for the transformation of breast cancer cells. In addition, the dysfunction and hypoxia of adipose tissue surrounding the breast cancer niche is another putative link that will be discussed. Finally, the mechanisms by which breast cancer cells evade checkpoints associated with nutrient overload will be examined. Experimentally validating these potential links will be important for prediction and treatment of breast cancer in patients with type 2 diabetes.
History
Journal
Journal of EndocrinologyVolume
237Issue
2Pagination
R35 - R46Publisher
BioScientificaLocation
Bradley Stok, Eng.Publisher DOI
ISSN
0022-0795eISSN
1479-6805Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2018, Society for EndocrinologyUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC